Plozasiran for high triglycerides and familial chylomicronemia
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests a new medicine called plozasiran that may lower very high triglyceride levels, which can reduce the risk of pancreatitis. It is for people with severe hypertriglyceridemia or a rare genetic condition called FCS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 15 years old (for FCS) or an adult (for SHTG).
- Your fasting triglyceride levels must be very high: at least 880 mg/dL for FCS, or at least 880 mg/dL (or 500 mg/dL with a history of pancreatitis) for SHTG.
- You must have a diagnosis of FCS or high-risk SHTG.
- You must be willing to follow a low-fat diet (no more than 20 grams of fat per day for FCS).
- If you have diabetes, it must be well-controlled (HbA1c less than 9%).
- You must agree to use effective birth control during the trial and for at least 90 days after the last dose.
- You must not have certain heart conditions, recent strokes, or other serious health issues as listed in the exclusion criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called plozasiran for people with severely high triglycerides that have already caused pancreatitis (inflammation of the pancreas). The goal is to see if the drug can lower triglycerides and help prevent future attacks.
This study tests a new medicine called olezarsen to lower very high triglycerides (fats) in the blood of children and teenagers with familial chylomicronemia syndrome (FCS), a rare genetic condition. The goal is to reduce the risk of pancreatitis and other complications.
This study tests a new medicine called solbinsiran (LY3561774) for people with very high triglyceride levels. It aims to see if it can lower these fats in your blood and reduce the risk of pancreatitis or heart problems.
This trial tests a new gene-editing treatment (CS-121) for children and teens with a rare inherited condition called Familial Chylomicronemia Syndrome (FCS). It aims to lower very high triglyceride levels and reduce the risk of pancreatitis.
This Phase 2 trial studies how well and how safely orlistat works over the long term for people who have very high triglycerides linked to rare genetic lipid disorders. It may help lower triglycerides and assess long-term side effects, but you must meet specific genetic, lab, and health requirements.
This study tests an investigational medication called DR10624 for people with very high triglycerides, a type of fat in the blood that can increase the risk of heart problems and pancreatitis. The trial aims to see if this drug can safely lower triglycerides better than standard care.
Hear when a new Familial Chylomicronemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.